Extramammary Paget Disease: A Review

Clicks: 13
ID: 326634
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #50 of 188 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 188 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Extramammary Paget disease (EMPD) is defined by the World Health Organisation (WHO), as 'a rare adenocarcinoma characterized by a predominant intraepithelial growth of neoplastic cells originating in the skin (primary EMPD) or representing intraepithelial spread of an underlying visceral carcinoma (secondary EMPD)'(1).It affects areas rich in apocrine glands, such as genital and perianal skin. First described by Radcliffe Crocker in 1889, EMPD often remains confined to the epidermis for years, following a quiescent course. Diagnosis is frequently delayed or missed due to its insidious onset and non-specific symptoms, which can mimic other inflammatory dermatoses. Importantly, EMPD is linked to underlying visceral malignancies although the risk varies anatomically. Data from England on EMPD incidence and 5-year survival from 2013 to 2020 shows crude incidence rate of 0.17 per 100,000 person-years (PY). Additionally, the 5-year net survival for EMPD diagnosed in 2013 was 90.9%. The reported net survival for EMPD is comparable to melanoma (89.6%), prostate (85.8%) and breast cancers (85.9%) overall i.e. for all stages combined. Management of EMPD focuses on identifying and addressing any associated underlying malignancies. Other treatment options include surgery or topical treatments, while non-surgical approaches such as radiotherapy and systemic treatment are used for advanced or metastatic disease. Treatment approaches may not be curative and recurrence rates can be up to 50%, highlighting the importance of close surveillance. This review covers EMPD's history, classification, epidemiology, aetiology, pathogenesis, diagnosis and highlights current strategies for malignancy screening and patient management. These findings are important as they contribute to our understanding of the trends and outcomes of this rare disease.
Reference Key
openalex_W7204592005 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Farishta Khan, Shweta Karakara, Zhenghao Wang, Honey Frimpong-Manso, Birgitta van Bodegraven, Jane Sterling, Paul Craig, Andrew Nordin, Zoe C Venables
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag377
URL
https://doi.org/10.1093/ced/llag377
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.